| Objective: To evaluate the safety of HPV (Human papillomavirus) vaccination among eligible female students in Hainan Province and analyze the factors influencing their mothers' participation in the HPV vaccination program. Methods: From November 2023 to January 2024, a questionnaire survey was conducted among 13- to 14.5-year-old girls and their mothers who participated in the HPV vaccination program in 18 counties and cities of Hainan Province. Data were statistically analyzed using Excel and SPSS 26.0. Statistical methods: The occurrence of adverse reactions to HPV vaccination among eligible female students was described by frequency and proportion. Univariate analysis was performed using chi-square test and t-test, and multivariate analysis was conducted using Logistic regression. A P value < 0.05 was considered statistically significant. Results: Among 6,163 eligible female students who received HPV vaccination, 3,883 had no adverse reactions, accounting for 63% of the total. The incidence of adverse reactions that affected daily activities was less than 5%. The HPV vaccination rate among mothers of eligible female students was 27.03%. Four factors, namely age (OR = 1.473, 95% CI: 1.326 - 1.637), educational level (OR = 0.887, 95% CI: 0.831 - 0.948), awareness of HPV and HPV vaccine (OR = 0.884, 95% CI: 0.870 - 0.898), and monthly family income (OR = 0.880, 95% CI: 0.813 - 0.952), were identified as influencing factors for mothers' participation in HPV vaccination (P < 0.05). Conclusion: The incidence of adverse reactions to HPV vaccination among eligible female students in Hainan Province is low, indicating high safety. Educational level, awareness of HPV and HPV vaccine, age, and monthly family income are the influencing factors for women in our province to receive HPV vaccination. Conducting relevant science popularization on cervical diseases, continuing to promote free two-cancer screening and HPV vaccination programs for eligible females will be conducive to advancing the global plan for eliminating cervical cancer. |
